Uterine sarcomas are rare tumors with a poor prognosis.
The main purpose of this phase II proof-of-principle- pilot study is to test the efficacy of
the hydroxamic acid-based Histone deacetylase inhibitor (HDACI) Vorinostat (SAHA) as
monotherapy in patients with HDAC-positive, progressive, metastatic uterine sarcomas and
mixed epithelial and mesenchymal tumors after prior anti-proliferative therapy.